Abstract
A novel, green, and atom-economical boric acid catalyzed direct amidation without the use of any coupling agents for the preparation of suberoylanilide hydroxamic acid (SAHA) and SAHA-based inhibitors targeting anti-proliferation of cancer cells is provided. The new SAHA-based inhibitor B123, when used alone, exhibited higher anti-proliferative activities than SAHA or Cisplatin against a number of human cancer cells. We have examined the effect of combination of these SAHA-based inhibitors with Cisplatin. We found synergistic effects of the combination of SAHA-based inhibitors with Cisplatin over a wide range of concentrations against human liver cancer cells HepG2 and two human lung cancer cell lines H1299 and H460. This synergism leads up to 8-fold of dose reduction for Cisplatin in the combination with our synthesized inhibitor B123 against H1299.
Keywords: Synergistic effect, anti-proliferation, SAHA-based inhibitors, Cisplatin, hydroxamic acids.
Medicinal Chemistry
Title:Synergistic Effect of the Combination of Novel Suberoylanilide Hydroxamic Acid Derivatives with Cisplatin on Anti-proliferation of Human Cancer Cells
Volume: 12 Issue: 8
Author(s): Rui Xie, Jinghua Shi, Chunhui Cheng, Fan Yun, Xia Liu, Pingwah Tang, Xinying Wu, Ming Yang and Qipeng Yuan
Affiliation:
Keywords: Synergistic effect, anti-proliferation, SAHA-based inhibitors, Cisplatin, hydroxamic acids.
Abstract: A novel, green, and atom-economical boric acid catalyzed direct amidation without the use of any coupling agents for the preparation of suberoylanilide hydroxamic acid (SAHA) and SAHA-based inhibitors targeting anti-proliferation of cancer cells is provided. The new SAHA-based inhibitor B123, when used alone, exhibited higher anti-proliferative activities than SAHA or Cisplatin against a number of human cancer cells. We have examined the effect of combination of these SAHA-based inhibitors with Cisplatin. We found synergistic effects of the combination of SAHA-based inhibitors with Cisplatin over a wide range of concentrations against human liver cancer cells HepG2 and two human lung cancer cell lines H1299 and H460. This synergism leads up to 8-fold of dose reduction for Cisplatin in the combination with our synthesized inhibitor B123 against H1299.
Export Options
About this article
Cite this article as:
Xie Rui, Shi Jinghua, Cheng Chunhui, Yun Fan, Liu Xia, Tang Pingwah, Wu Xinying, Yang Ming and Yuan Qipeng, Synergistic Effect of the Combination of Novel Suberoylanilide Hydroxamic Acid Derivatives with Cisplatin on Anti-proliferation of Human Cancer Cells, Medicinal Chemistry 2016; 12 (8) . https://dx.doi.org/10.2174/1573406412666160404125551
DOI https://dx.doi.org/10.2174/1573406412666160404125551 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patient-Specific Alpha-Particle Dosimetry
Current Radiopharmaceuticals Prolonged Adrenal Insufficiency After the Discontinuation of Mitotane Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Current Pharmaceutical Design Role of Flavonoids in Future Anticancer Therapy by Eliminating the Cancer Stem Cells
Current Stem Cell Research & Therapy Laccases in Pharmaceutical Chemistry: A Comprehensive Appraisal
Mini-Reviews in Organic Chemistry Hodgkin Lymphoma in HIV Positive Patients
Current HIV Research Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets In vitro Measurement and In vivo Prediction of Time-Dependent Inhibitory Effects of Three Tyrosine Kinase Inhibitors on CYP3A Activity
Current Drug Metabolism Multifunctional Materials for Cancer Therapy: From Antitumoral Agents to Innovative Administration
Current Organic Chemistry Disposition and Interaction of Biotherapeutics in Pediatric Populations
Current Drug Metabolism Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry Human UDP-Glucuronosyltransferase 2B7
Current Drug Metabolism The “Tilted Peptide Theory” Links Membrane Insertion Properties and Fusogenicity of Viral Fusion Peptides
Protein & Peptide Letters Isoform Characterisation, Heterologous Expression and Functional Analysis of Two Lectins from Vatairea macrocarpa
Protein & Peptide Letters Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets Unmasking the Many Faces of Giloy (<i>Tinospora cordifolia</i> L.): A Fresh Look on its Phytochemical and Medicinal Properties
Current Pharmaceutical Design Ultrasound-based Radiomics Predicts Short-term Outcomes in Hepatitis B Virus-related Acute-on-chronic Liver Failure
Current Medical Imaging Imaging Cellular Receptors in Breast Cancers: An Overview
Current Pharmaceutical Biotechnology Peptide Therapeutics and the Pharmaceutical Industry: Barriers Encountered Translating from the Laboratory to Patients
Current Medicinal Chemistry A Brief Review of the Essential Role of Nanovehicles for Improving the Therapeutic Efficacy of Pharmacological Agents Against Tumours
Current Drug Delivery